Ignite Creation Date:
2025-12-24 @ 10:56 PM
Ignite Modification Date:
2026-02-25 @ 4:58 PM
Study NCT ID:
NCT00566969
Status:
COMPLETED
Last Update Posted:
2020-04-02
First Post:
2007-12-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Cocaine Withdrawal and Pharmacotherapy Response
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019970', 'term': 'Cocaine-Related Disorders'}, {'id': 'D009293', 'term': 'Opioid-Related Disorders'}], 'ancestors': [{'id': 'D019966', 'term': 'Substance-Related Disorders'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D000079524', 'term': 'Narcotic-Related Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000073893', 'term': 'Sugars'}, {'id': 'D000077261', 'term': 'Carvedilol'}], 'ancestors': [{'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D011412', 'term': 'Propanolamines'}, {'id': 'D000605', 'term': 'Amino Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D020005', 'term': 'Propanols'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D002227', 'term': 'Carbazoles'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006575', 'term': 'Heterocyclic Compounds, 3-Ring'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'mehmet.sofuoglu@yale.edu', 'phone': '203-932-5711', 'title': 'Mehmet Sofuoglu, M.D.,Ph.D.', 'phoneExt': '4809', 'organization': 'Yale University'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': '5 years', 'eventGroups': [{'id': 'EG000', 'title': 'Sugar Pill', 'description': 'To be compared to active drug\n\nsugar pill: randomly given 25mg or 50mg of a sugar pill or the active comparator', 'otherNumAtRisk': 19, 'otherNumAffected': 14, 'seriousNumAtRisk': 19, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Carvedilol 25 mg', 'description': 'To be compared to sugar pill\n\ncarvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.', 'otherNumAtRisk': 28, 'otherNumAffected': 13, 'seriousNumAtRisk': 28, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Carvedilol 50 mg', 'description': 'To be compared to sugar pill\n\ncarvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.', 'otherNumAtRisk': 23, 'otherNumAffected': 13, 'seriousNumAtRisk': 23, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Disturbed concentration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Agitation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 11, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Tiredness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Drowsiness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 14, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Nightmares', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 11, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 10, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 11, 'numAffected': 11}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Numbness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Cramps', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 9, 'numAffected': 9}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 8, 'numAffected': 8}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 13, 'numAffected': 13}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 11, 'numAffected': 11}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 13, 'numAffected': 13}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}, {'term': 'Decreased appetitie', 'stats': [{'groupId': 'EG000', 'numAtRisk': 19, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 28, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 23, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'BSI'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percent Days Abstinent From Cocaine - Self Report', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Sugar Pill', 'description': 'To be compared to active drug\n\nsugar pill: randomly given 25mg or 50mg of a sugar pill or the active comparator'}, {'id': 'OG001', 'title': 'Carvedilol 25 mg', 'description': 'To be compared to sugar pill\n\ncarvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.'}, {'id': 'OG002', 'title': 'Carvedilol 50 mg', 'description': 'To be compared to sugar pill\n\ncarvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.'}], 'classes': [{'categories': [{'measurements': [{'value': '72.9', 'spread': '25.3', 'groupId': 'OG000'}, {'value': '72.9', 'spread': '29', 'groupId': 'OG001'}, {'value': '59.3', 'spread': '31.7', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '.10', 'groupIds': ['OG000', 'OG001', 'OG002'], 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE_LEGACY', 'nonInferiorityComment': 'A hierarchical linear model was used to account for unequal variance and covariance structures across time.'}], 'paramType': 'MEAN', 'timeFrame': '11 weeks', 'description': 'Percent Self reported days of abstinence from any cocaine use during the 11 week trial.', 'unitOfMeasure': 'percentage of days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Sugar Pill', 'description': 'To be compared to active drug\n\nsugar pill: randomly given 25mg or 50mg of a sugar pill or the active comparator'}, {'id': 'FG001', 'title': 'Carvedilol 25 mg', 'description': 'To be compared to sugar pill\n\ncarvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.'}, {'id': 'FG002', 'title': 'Carvedilol 50 mg', 'description': 'To be compared to sugar pill\n\ncarvedilol: randomly assigned to 25mg or 50mg of Carvedilol or sugar pill, dose determined by height and weight.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '34'}, {'groupId': 'FG001', 'numSubjects': '37'}, {'groupId': 'FG002', 'numSubjects': '35'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '19'}, {'groupId': 'FG001', 'numSubjects': '28'}, {'groupId': 'FG002', 'numSubjects': '23'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '12'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'BG000'}, {'value': '37', 'groupId': 'BG001'}, {'value': '35', 'groupId': 'BG002'}, {'value': '106', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Sugar Pill', 'description': 'To be compared to active drug\n\nsugar pill: Subjects randomized to placebo, carvedilol 25mg or 50mg'}, {'id': 'BG001', 'title': 'Carvedilol 25 mg', 'description': 'To be compared to placebo and Carvedilol 50 mg\n\ncarvedilol: subjects randomized to placebo, carvedilol 25mg or 50mg'}, {'id': 'BG002', 'title': 'Carvedilol 50 mg', 'description': 'To be compared to placebo and Carvedilol 25 mg\n\nCarvedilol: subjects randomized to placebo, carvedilol 25mg or 50mg'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '37.6', 'spread': '9.1', 'groupId': 'BG000'}, {'value': '37.7', 'spread': '10.9', 'groupId': 'BG001'}, {'value': '39.1', 'spread': '10.9', 'groupId': 'BG002'}, {'value': '38.1', 'spread': '10.3', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '40', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '19', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '24', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '26', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '21', 'groupId': 'BG000'}, {'value': '24', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '70', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '10', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': '106 subjects meeting inclusion criteria who were without exclusions and randomized to an intervention.'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 106}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-03', 'completionDateStruct': {'date': '2013-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-03-31', 'studyFirstSubmitDate': '2007-12-03', 'resultsFirstSubmitDate': '2016-08-16', 'studyFirstSubmitQcDate': '2007-12-03', 'lastUpdatePostDateStruct': {'date': '2020-04-02', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2016-08-16', 'studyFirstPostDateStruct': {'date': '2007-12-04', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-10-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percent Days Abstinent From Cocaine - Self Report', 'timeFrame': '11 weeks', 'description': 'Percent Self reported days of abstinence from any cocaine use during the 11 week trial.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['cocaine, opiate, methadone, carvedilol'], 'conditions': ['Cocaine Dependence', 'Opiate Dependence']}, 'descriptionModule': {'briefSummary': 'A total of 120 male and female opioid dependent cocaine users will participate in this study. This study will be a 8-week double-blind, placebo controlled study examining the dose-dependent effects of carvedilol (up to 50 mg/day) in methadone stabilized patients. The design will have two phases: 1) a four-week "treatment " phase; and 2) a 4 week " taper and detoxification or transfer" phase. Subjects will be cocaine users who are on stable doses of methadone (60 to 140 mg/day). Carvedilol dose will be increased from 12.5mg/day to the target dose of either 25 or 50 mg/day as tolerated. At the end of the treatment-phase, subjects will undergo detoxification from methadone over a 2 to 4-week period based on an individual\'s needs, and they will concurrently be tapered off carvedilol.', 'detailedDescription': 'The adrenergic neurotransmission serves multiple functions including learning, emotional processing and stress response to psychological and physical challenges (Huether, 1996; Sved et al., 2001). Adrenergic transmission also mediates drug withdrawal states and stress-induced relapse to drug use (Aston-Jones et al., 2004; Stewart, 2000). Consistent with these preclinical findings, adrenergic blockers showed promise as a treatment of cocaine dependence (Kampman et al., 2001b; Kampman et al., 2006). These preliminary findings are significant because there are no proven pharmacotherapies for cocaine addiction although an estimated 2.3 million of Americans aged 12 or older are regular cocaine users (SAMHSA, 2004). The societal cost of cocaine addiction is estimated to be $45 billion in the US, suggesting that development of even modestly effective cocaine pharmacotherapies will have great economic benefits. For example, availability of a medication decreasing cocaine use by 10 percent is estimated to have $745 million economic benefit in the US alone (Cartwright, 2000). Thus, developing effective treatments for cocaine addiction is an essential goal with significant benefits both for the society and the individual.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Current opioid dependence as evidenced by documented prior treatment for opioid dependence or signs of opiate withdrawals, self-reported history of opioid dependence for a consecutive 12 month period and a positive urine for opiates.\n* Current cocaine use with self-reported use of cocaine \\> 1 time/week in at least on month preceding study entry, provision of a cocaine-positive urine and fulfilled DSM-IV criteria for cocaine dependence\n* For women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy and monthly pregnancy tests.\n\nExclusion Criteria:\n\n* current diagnosis of other drug or alcohol dependence (other than opiates, cocaine or tobacco);\n* serious medical illness including asthma, diabetes, bradycardia, or other arrhythmias and major cardiovascular, renal, endocrine, hepatic disorders;\n* current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder or significant current suicidal or homicidal thoughts;\n* screening liver function tests (AST or ALT) greater than 3 times normal;\n* known allergy or intolerance for carvedilol or methadone.'}, 'identificationModule': {'nctId': 'NCT00566969', 'acronym': 'Carvedilol', 'briefTitle': 'Cocaine Withdrawal and Pharmacotherapy Response', 'organization': {'class': 'OTHER', 'fullName': 'Yale University'}, 'officialTitle': 'Cocaine Withdrawal and Pharmacotherapy Response', 'orgStudyIdInfo': {'id': '0704002562'}, 'secondaryIdInfos': [{'id': 'R01DA014537', 'link': 'https://reporter.nih.gov/quickSearch/R01DA014537', 'type': 'NIH'}, {'id': 'DPMC', 'type': 'OTHER', 'domain': 'NIDA'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Sugar Pill', 'description': 'To be compared to active drug', 'interventionNames': ['Drug: sugar pill']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Carvedilol 25 mg', 'description': 'To be compared to placebo and Carvedilol 50 mg', 'interventionNames': ['Drug: Carvedilol 25 mg']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Carvedilol 50 mg', 'description': 'To be compared to placebo and Carvedilol 25 mg', 'interventionNames': ['Drug: Carvedilol 50 mg']}], 'interventions': [{'name': 'sugar pill', 'type': 'DRUG', 'otherNames': ['placebo'], 'description': 'Subjects randomized to placebo, carvedilol 25mg or 50mg', 'armGroupLabels': ['Sugar Pill']}, {'name': 'Carvedilol 25 mg', 'type': 'DRUG', 'otherNames': ['Coreg'], 'description': 'subjects randomized to placebo, carvedilol 25mg or 50mg', 'armGroupLabels': ['Carvedilol 25 mg']}, {'name': 'Carvedilol 50 mg', 'type': 'DRUG', 'otherNames': ['Coreg'], 'description': 'subjects randomized to placebo, carvedilol 25mg or 50mg', 'armGroupLabels': ['Carvedilol 50 mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06516', 'city': 'West Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Veterans Hospital', 'geoPoint': {'lat': 41.27065, 'lon': -72.94705}}], 'overallOfficials': [{'name': 'Mehmet Sofuoglu, M.D., Ph.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Yale University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Yale University', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute on Drug Abuse (NIDA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}